Cloudberry seeds have a significant antimicrobial activity against MRSA
The number of refractory wound infections caused by methicillin-resistant Staphylococcus aureus or MRSA has increased.
A joint project of HUS Helsinki University Hospital, VTT Technical Research Centre of Finland Ltd, University of Turku, and Hospital Universitario Principe de Astúrias together with the research institute Fundación Jiménez Díaz from Spain investigated the efficacy of compounds fractionated from berries against microbes that cause wound infections. Ellagitannins, compounds fractionated from cloudberry seeds, have a significant antimicrobial activity against MRSA.
“A resistant bacterium becomes susceptible to antibiotics and the formation of biofilms is reduced when compounds fractionated from berries are added to it. Ellagitannins from cloudberry significantly inhibited the growth of MRSA in test tube conditions and speeded up the recovery of a wound caused by these bacteria in a mouse model”, says Teemu Kinnari, ENT Specialist and Chief Physician at HUS.
Berries contain efficient antimicrobial compounds
Berries and their side-streams, i.e. surplus ingredients from the berry industry, have so far been used in the food and cosmetics industry. VTT has a long tradition of researching arctic berries, and has previously shown that they contain effective antimicrobial compounds.
The joint project utilised VTT InnoBerry Technologies™ developed and patented by VTT to enrich and fractionate antimicrobial ellagitannin compounds from wild berries. Previously unutilised cloudberry side-streams from the berry industry were used as source material. No organic solvents were used in the extraction method, and thus the water-soluble product is suitable for various uses.
“We were able to use an environmentally friendly approach to fractionate ellagitannins whose antimicrobial potential may be used for several applications. An example of an interesting application is skin treatment against MRSA prior to surgery, in addition to treating severe wound infections”, says Hanna-Leena Alakomi, expert in microbiology and Research Team Leader at VTT.
Similar compounds can be found in other Finnish plant species
VTT’s ellagitannins fractionated from seeds were purified at Department of Chemistry of the University of Turku. Pure substances gave a more reliable picture of the activity of specific ellagitannins against MRSA.
“It is important to have precise knowledge about the compounds that are relevant for the activity of various products. This means that researched information can be used to find even more effective substances among the plant kingdom. For example, Finnish plants contain plenty of compounds similar to cloudberry ellagitannins that could have corresponding or even better activity against MRSA”, says Juha-Pekka Salminen, Professor of Natural Compound Chemistry at the University of Turku.
Keywords
Contacts
HUS
Specialist, Chief Physician Teemu Kinnari
teemu.kinnari@hus.fi
VTT Technical Research Centre of Finland
Research Team Leader Hanna-Leena Alakomi and Senior Research Scientist Liisa Nohynek
hanna-leena.alakomi@vtt.fi; liisa.nohynek@vtt.fi
University of Turku
Professor of Natural Compound Chemistry Juha-Pekka Salminen
j-p.salminen@utu.fi
About HUS
At HUS Helsinki University Hospital about 680 000 patients receive medical care annually. We have almost 27,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.
HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Eksjukhuset öppnar sina dörrar för patienter i maj24.4.2025 15:00:00 EEST | Pressmeddelande
Eksjukhuset som fokuserar på behandling av ögonsjukdomar öppnar i Mejlans i Helsingfors den 12 maj 2025. Eksjukhuset ger bättre beredskap att svara mot det ökade vårdbehovet inom ögonsjukdomar.
Tammisairaala avaa ovensa potilaille toukokuussa24.4.2025 15:00:00 EEST | Tiedote
HUSin silmäsairauksien hoitoon keskittyvä Tammisairaala avautuu Helsingin Meilahteen 12.5.2025. Tammisairaala parantaa valmiuksia vastata kasvavaan silmäsairauksien hoitotarpeeseen.
Oak Hospital opens in May24.4.2025 15:00:00 EEST | Press release
HUS Oak Hospital focusing on the treatment of eye diseases opens in Meilahti, Helsinki on May 12, 2025. Oak Hospital will improve the capacity to respond to the increasing need for ophthalmological treatment.
Samarbetsförhandlingar påbörjas inom HUS Bastjänster24.4.2025 13:01:45 EEST | Pressmeddelande
Förhandlingarna omfattar 200 personer som arbetar med uppgifter inom lokalvården. Det uppskattade minskningsbehovet är högst 200 personer. Bakgrunden till förhandlingarna är att ansvaret för Helsingfors stads lokalvårdstjänsterna för socialvårdens verksamhetsställen överförs till stadens egen regi.
HUSin Runkopalveluissa aloitetaan yhteistoimintaneuvottelut24.4.2025 13:01:45 EEST | Tiedote
Neuvotteluiden piirissä on 200 laitoshuollon tehtävissä työskentelevää henkilöä. Arvioitu vähennystarve on enintään 200 henkilöä. Neuvottelujen taustalla on Helsingin kaupungin sosiaalihuollon toimipisteiden laitoshuoltopalveluiden siirtyminen kaupungin omalle vastuulle.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom